Price movement over the last 24 hours
ADMA Biologics Inc vs American States Water Company — how do they compare? ADMA Biologics Inc trades at $9.24 (market cap $2.13B), while American States Water Company trades at $84.03 (market cap $3.26B). The key difference: American States Water Company is the larger of the two by market cap, and American States Water Company pays a 2.42% dividend while ADMA Biologics Inc pays none. Which is the better fit depends on your goals.
| ADMA | AWR | |
|---|---|---|
Market Cap | $2.13B | $3.26B |
Sector | Health | Utilities |
52-Week High | $20.38 | $84.76 |
52-Week Low | $7.60 | $70.10 |
Enterprise Value | $2.20B | $4.17B |
Dividend Yield | — | 2.42% |
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.
The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.
American States Water (AWR) trades at $83.14, down 1.91% on the day, with a bullish technical outlook supported by moving averages. The company maintains strong fundamentals with 19.66% net margins and consistent dividend growth, though recent earnings show mixed quarterly performance. Recent news highlights AWR's defensive utility characteristics and completion of a $200 million equity offering program.
AWR presents a stable investment case with reliable dividend income and utility sector defensiveness, though valuation appears elevated at 24.24 P/E. Key risks include regulatory rate pressures and execution of capital investments. Analyst sentiment remains cautious with only 20% buy ratings, suggesting limited near-term upside potential despite the company's operational strength.
Trailing returns across standard periods
Latest headlines on both assets
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →American States Water provides water and electric services to over one million people in the U.S. It also manages water and wastewater systems for various military bases under long-term privatization contracts.
Read more on AWR →